BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Cambridge Science Centre hosted a special event to honour the scientists and organisations that help bring its interactive ...

The top opportunities in the genomic data analysis and interpretation market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $756.71 million ...